MedKoo Cat#: 407189 | Name: GSK-LSD1 dihydrochloride
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1). GSK-LSD1 potently inhibits proliferation of varies cancer cell lines by changing gene expression patterns. GSK-LSD1 inhibits LSD1 with an IC50 of 16 nM and is > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B). GSK-LSD1 induces gene expression changes in cancer cell lines (average EC50 < 5 nM) and inhibits cancer cell line growth (average EC50 < 5 nM). Lysine specific demethylase 1 (LSD1) is a histone demethylase found in various transcriptional co-repressor complexes. LSD1 is involved in ES cell differentiation, hematopoiesis, and has been described as having a role in Acute Myeloid Leukemia (AML). (http://www.thesgc.org/chemical-probes/GSK-LSD1)

Chemical Structure

GSK-LSD1 dihydrochloride
GSK-LSD1 dihydrochloride
CAS#1821798-25-7 (2HCl)

Theoretical Analysis

MedKoo Cat#: 407189

Name: GSK-LSD1 dihydrochloride

CAS#: 1821798-25-7 (2HCl)

Chemical Formula: C14H22Cl2N2

Exact Mass: 0.0000

Molecular Weight: 289.24

Elemental Analysis: C, 58.14; H, 7.67; Cl, 24.51; N, 9.69

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,850.00 Ready to ship
1g USD 4,250.00 Ready to ship
2g USD 6,850.00 2 weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
2102933-95-7 (rel-2HCl) 1431367-49-5 (rel-HCl) 1431368-48-7 (rel-free base) 1821798-25-7 (2HCl) 1431367-51-9 (HCl) 1431368-50-1 (free base)
Synonym
GSK-LSD1 dihydrochloride; GSK-LSD1 HCl; GSK-LSD1 2HCl; GSK-LSD1; GSK-LSD-1; GSK-LSD 1;
IUPAC/Chemical Name
N-((1R,2S)-2-phenylcyclopropyl)piperidin-4-amine dihydrochloride
InChi Key
PJFZOGMSPBHPNS-WICJZZOFSA-N
InChi Code
InChI=1S/C14H20N2.2ClH/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12;;/h1-5,12-16H,6-10H2;2*1H/t13-,14+;;/m0../s1
SMILES Code
[H]Cl.[H]Cl.C1(N[C@H]2[C@H](C3=CC=CC=C3)C2)CCNCC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
GSK-LSD1 inhibits LSD1 with an IC50 of 16 nM and is > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).
In vitro activity:
Additionally, the EGF-induced proliferation of HSC-3 cells was inhibited by 1 and 10 μM GSK-LSD1 (Figure 4B). Molecular signaling analysis showed that GSK-LSD1 inhibits phospho-AKT, -ERK1/2 and -NF-κB-p65 in HSC-3 cells (Figure 4C and 4D). Thus, GSK-LSD1 inhibits EGF-induced signaling and proliferation without cytotoxicity in oral cancer cells. This represents a potential mechanism for the inhibitory effects of GSK-LSD1. Reference: Oncotarget. 2017 Sep 26; 8(43): 73372–73386. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650269/
In vivo activity:
GSK-LSD1–treated mice exhibited a lower proportion of GFP+ cells in the bone marrow (Figure 1A), peripheral blood, and spleen (supplemental Figure 1B-C). Other measures of disease burden, including spleen weight, were markedly reduced in the setting of GSK-LSD1 treatment (supplemental Figure 1E). Mice treated with GSK-LSD1 exhibited a significant decline in platelet count (P = .003; supplemental Figure 1D), which is consistent with an on-target effect of LSD1 depletion. Immunophenotyping of bone marrow cells after 3 days of GSK-LSD1 treatment revealed a reduction of more primitive GFP+ leukemia cells coexpressing c-kit and Mac-1 (Figure 1B). GSK-LSD1–treated mice also had markedly improved survival (median survival, 78 days) compared with control mice (median survival, 39 days) (Figure 1C). Reference: Blood. 2018 Apr 12; 131(15): 1730–1742. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897868/

Preparing Stock Solutions

The following data is based on the product molecular weight 289.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Wang Z, Long QY, Chen L, Fan JD, Wang ZN, Li LY, Wu M, Chen X. Inhibition of H3K4 demethylation induces autophagy in cancer cell lines. Biochim Biophys Acta Mol Cell Res. 2017 Dec;1864(12):2428-2437. doi: 10.1016/j.bbamcr.2017.08.005. Epub 2017 Aug 8. PMID: 28800922. 2. Alsaqer SF, Tashkandi MM, Kartha VK, Yang YT, Alkheriji Y, Salama A, Varelas X, Kukuruzinska M, Monti S, Bais MV. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8(43):73372-73386. doi: 10.18632/oncotarget.19637. PMID: 29088714; PMCID: PMC5650269. 3. Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. 2018 Apr 12;131(15):1730-1742. doi: 10.1182/blood-2017-09-807024. Epub 2018 Feb 16. PMID: 29453291; PMCID: PMC5897868.
In vitro protocol:
1. Wang Z, Long QY, Chen L, Fan JD, Wang ZN, Li LY, Wu M, Chen X. Inhibition of H3K4 demethylation induces autophagy in cancer cell lines. Biochim Biophys Acta Mol Cell Res. 2017 Dec;1864(12):2428-2437. doi: 10.1016/j.bbamcr.2017.08.005. Epub 2017 Aug 8. PMID: 28800922. 2. Alsaqer SF, Tashkandi MM, Kartha VK, Yang YT, Alkheriji Y, Salama A, Varelas X, Kukuruzinska M, Monti S, Bais MV. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8(43):73372-73386. doi: 10.18632/oncotarget.19637. PMID: 29088714; PMCID: PMC5650269.
In vivo protocol:
1. Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. 2018 Apr 12;131(15):1730-1742. doi: 10.1182/blood-2017-09-807024. Epub 2018 Feb 16. PMID: 29453291; PMCID: PMC5897868. 2. Alsaqer SF, Tashkandi MM, Kartha VK, Yang YT, Alkheriji Y, Salama A, Varelas X, Kukuruzinska M, Monti S, Bais MV. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Jul 27;8(43):73372-73386. doi: 10.18632/oncotarget.19637. PMID: 29088714; PMCID: PMC5650269.